Overview

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Ramucirumab